Trials & Filings

CPI-613 begins Ph. II Trial Against MDS

Cornerstone AEMD treatment tested

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Cornerstone Pharmaceuticals, Inc. has begun a Phase II trial of CPI-613, its lead Altered Energy Metabolism Directed (AEMD) drug candidate. The pilot study, sponsored by the Comprehensive Cancer Center of Wake Forest Baptist Medical Center, will evaluate the overall response rate for CPI-613 in patients with myelodysplastic syndrome (MDS) who have been unresponsive to previous therapies. Secondary endpoints include overall survival, progression-free survival, safety, and transfusion frequency. ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters